Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows (Unaudited)

v3.20.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Cash flows from operating activities:        
Net loss from ongoing operations $ (2,916,040) $ (820,844) $ (9,046,637) $ (2,703,105)
Net income/(loss) from discontinued operations (4,211,157) (16,182) (5,247,227) 154,230
Adjustments to reconcile net loss to net cash used in operating activities:        
Loss/(gain) on sale of securities 0 (6,416) 36,714 (2,155)
Gain on fair market value of equity investments (31,465) (31,465)
Accrued loss on marketable securities     1,749 6,289
Depreciation and amortization 13,087 28,757 54,522
Loss on disposal of fixed assets     18,680
Impairment of Prepaid Royalties 291,442
Impairment of intangible assets 152,822
Inventory adjustment for net realizable value 197,723
Reserve for obsolete inventory 79,413 126,422
Reserve for doubtful other receivables     105,325
Change in assets and liabilities        
Decrease/(increase) in trade receivables     67,122 (59,899)
Decrease in deposits and other receivables     9,347
Decrease in inventories     1,262 46,786
(Increase)/decrease in prepaid expenses     (98,410) 18,147
Decrease in other assets     2,722 4,330
Increase/(decrease) in trade and other payables     961,134 (600,537)
Increase in right-of-use liabilities     37
Net cash used by operating activities     (8,842,867) (2,572,578)
Cash flows from investing activities:        
Short-term note receivable     (100,000)
Purchases of marketable securities     (100,865) (87,305)
Proceeds from sale of marketable securities     2,310,898 2,556,516
Net cash provided by investing activities     2,210,033 2,369,211
Cash flows from financing activities        
Net proceeds from issuance of common stock     14,564,961
Net proceeds from the exercise of Series C Convertible Preferred warrants for the purchase of common stock     7,740,000
Net proceeds from the exercise of prepaid equity forward contracts for the purchase of common stock     80
Net cash provided by financing activities     22,305,041
Net increase/(decrease) in cash and restricted cash     15,672,207 (203,367)
Cash and restricted cash at beginning of period     632,538 681,755
Cash and restricted cash at end of period $ 16,304,745 $ 478,388 16,304,745 478,388
Cash paid for:        
Interest    
Income Taxes    
Supplemental Schedule of Non-Cash Financing and Investing Activities        
Net unrealized gains/(losses) on marketable securities     45,597
Operating lease right-of-use asset obtained in exchange for lease obligation     (79,942)
Exercise of Series D Convertible Preferred Stock for Common Stock     273,955
Vendors [Member]        
Adjustments to reconcile net loss to net cash used in operating activities:        
Share based compensation     7,318
Chubeworkx [Member]        
Adjustments to reconcile net loss to net cash used in operating activities:        
Share based compensation     2,510,000
Cystron [Member]        
Adjustments to reconcile net loss to net cash used in operating activities:        
Share based compensation     1,233,057
Restricted Stock [Member] | Employee [Member]        
Adjustments to reconcile net loss to net cash used in operating activities:        
Share based compensation     25,555
Restricted Stock Units (RSUs) [Member] | Director [Member]        
Adjustments to reconcile net loss to net cash used in operating activities:        
Share based compensation     $ 70,333 $ 242,165